Rapilysin

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

reteplaza

Available from:

Actavis Group PTC ehf

ATC code:

B01AD07

INN (International Name):

reteplase

Therapeutic group:

Antitrombotična sredstva

Therapeutic area:

Miokardni infarkt

Therapeutic indications:

Rapilysin is indicated for the thrombolytic treatment of suspected myocardial infarction with persistent ST elevation or recent left bundle branch block within 12 hours after the onset of acute-myocardial-infarction (AMI) symptoms.

Product summary:

Revision: 27

Authorization status:

Pooblaščeni

Authorization date:

1996-08-29

Patient Information leaflet

                                17
8.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP
9.
POSEBNA NAVODILA ZA SHRANJEVANJE
Shranjujte pri temperaturi do 25
°
C
Vialo shranjujte v zunanji ovojnini za zagotovitev zaščite pred
svetlobo
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Actavis Group PTC ehf.
Dalshraun 1
220 Hafnarfjörður
Islandija
12.
ŠTEVILKA(E) DOVOLJENJA(DOVOLJENJ) ZA PROMET
EU/1/96/018/001
13.
ŠTEVILKA SERIJE
Lot
14.
NAČIN IZDAJANJA ZDRAVILA
15.
NAVODILA ZA UPORABO
16.
PODATKI V BRAILLOVI PISAVI

17.
EDINSTVENA OZNAKA – DVODIMENZIONALNA ČRTNA KODA_ _
Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.
18.
EDINSTVENA OZNAKA – V BERLJIVI OBLIKI_ _
PC:
SN:
NN:
18
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH
OVOJNINAH
Nalepka na viali
1.
IME ZDRAVILA IN POT(I) UPORABE
Rapilysin 10 enot prašek in vehikel za raztopino za injiciranje
reteplaza
za intravensko uporabo
2.
POSTOPEK UPORABE
Raztopino uporabite takoj po rekonstituciji
3.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP
4.
ŠTEVILKA SERIJE
Lot
5.
VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ENOT
10 enot reteplaze
6.
DRUGI PODATKI
19
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH
OVOJNINAH
Nalepka na injekcijski brizgi
1.
IME ZDRAVILA IN POT(I) UPORABE
Voda za injekcije
2.
POSTOPEK UPORABE
3.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP
4.
ŠTEVILKA SERIJE
Lot
5.
VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ENOT
10 ml
6.
DRUGI PODATKI
20
B. NAVODILO ZA UPORABO
21
NAVODILO ZA UPORABO
RAPILYSIN 10 ENOT PRAŠEK IN VEHIKEL ZA RAZTOPINO ZA INJICIRANJE
reteplaza
PRED ZAČETKOM UPORABE ZDRAVILA NATANČNO PREBERITE NAVODILO, KER
VSEBUJE ZA VAS POMEMBNE
PODATKE!
-
Navodilo shranite. Morda ga boste želeli ponovno prebrati.
-
Če imate dodatna vprašanja, se posvetujte z zdravnikom ali
farmacevtom.
-
Če opazite kateri koli neželeni učinek, 
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
2
1.
IME ZDRAVILA
Rapilysin 10 enot prašek in vehikel za raztopino za injiciranje
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
_ _
1 viala vsebuje 10 enot* reteplaze** v 0,56 g praška.
1 napolnjena injekcijska brizga vsebuje 10 ml vode za injekcije.
Pripravljena raztopina vsebuje 1 enoto reteplaze na ml.
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
*Jakost reteplaze se izraža v enotah (U) z uporabo referenčnega
standarda, ki je specifičen za reteplazo
in ni primerljiv z enotami, uporabljenimi za druge trombolitične
učinkovine.
**Rekombinantni aktivator plazminogena pridobljen s tehnologijo
rekombinantne DNA iz bakterije
_Escherichia coli. _
3.
FARMACEVTSKA OBLIKA
Prašek in vehikel za raztopino za injiciranje.
Bel prašek in bistra brezbarvna tekočina (voda za injekcije).
4.
KLINIČNI PODATKI
4.1
TERAPEVTSKE INDIKACIJE
Zdravilo Rapilysin je indicirano za trombolitično zdravljenje
domnevnega miokardnega infarkta s
trajno povišanim intervalom ST ali nedavnim levokračnim blokom v 12
urah po pojavu simptomov
akutnega miokardnega infarkta.
4.2
ODMERJANJE IN NAČIN UPORABE
Zdravljenje z reteplazo je treba začeti čim prej po pojavu simptomov
akutnega miokardnega infarkta.
Zdravilo Rapilysin naj predpisujejo zdravniki z izkušnjami pri
uporabi trombolitičnega zdravljenja in z
zmožnostjo spremljanja tega zdravljenja.
Odmerjanje
_Odmerjanje zdravila Rapilysin _
Zdravilo Rapilysin se daje kot bolus 10 enot, kateremu sledi drugi
bolusni odmerek 10 enot 30 minut
pozneje (dvojni bolus).
Vsak bolus damo kot počasno intravensko injekcijo v 2 minutah. Paziti
moramo, da pomotoma ne
injiciramo paravensko.
_HEPARIN IN ACETILSALICILNO KISLINO _
naj se za zmanjšanje tveganja za ponovno trombozo da pred
dajanjem zdravila Rapilysin in po njem.
_Odmerjanje heparina _
Priporočeni odmerek heparina je 5000 i.e., dan kot bolusna injekcija
pred zdravljenjem z reteplazo, ki
mu sledi infuzija 1000 i.e. na uro, ki začne teči po drugem bolusu
reteplaze. Heparin je treba daja
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 01-06-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 01-06-2023
Public Assessment Report Public Assessment Report Bulgarian 09-03-2016
Patient Information leaflet Patient Information leaflet Spanish 01-06-2023
Public Assessment Report Public Assessment Report Spanish 09-03-2016
Patient Information leaflet Patient Information leaflet Czech 01-06-2023
Public Assessment Report Public Assessment Report Czech 09-03-2016
Patient Information leaflet Patient Information leaflet Danish 01-06-2023
Public Assessment Report Public Assessment Report Danish 09-03-2016
Patient Information leaflet Patient Information leaflet German 01-06-2023
Public Assessment Report Public Assessment Report German 09-03-2016
Patient Information leaflet Patient Information leaflet Estonian 01-06-2023
Public Assessment Report Public Assessment Report Estonian 09-03-2016
Patient Information leaflet Patient Information leaflet Greek 01-06-2023
Public Assessment Report Public Assessment Report Greek 09-03-2016
Patient Information leaflet Patient Information leaflet English 01-06-2023
Public Assessment Report Public Assessment Report English 09-03-2016
Patient Information leaflet Patient Information leaflet French 01-06-2023
Public Assessment Report Public Assessment Report French 09-03-2016
Patient Information leaflet Patient Information leaflet Italian 01-06-2023
Public Assessment Report Public Assessment Report Italian 09-03-2016
Patient Information leaflet Patient Information leaflet Latvian 01-06-2023
Public Assessment Report Public Assessment Report Latvian 09-03-2016
Patient Information leaflet Patient Information leaflet Lithuanian 01-06-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 01-06-2023
Public Assessment Report Public Assessment Report Lithuanian 09-03-2016
Patient Information leaflet Patient Information leaflet Hungarian 01-06-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 01-06-2023
Public Assessment Report Public Assessment Report Hungarian 09-03-2016
Patient Information leaflet Patient Information leaflet Maltese 01-06-2023
Public Assessment Report Public Assessment Report Maltese 09-03-2016
Patient Information leaflet Patient Information leaflet Dutch 01-06-2023
Public Assessment Report Public Assessment Report Dutch 09-03-2016
Patient Information leaflet Patient Information leaflet Polish 01-06-2023
Public Assessment Report Public Assessment Report Polish 09-03-2016
Patient Information leaflet Patient Information leaflet Portuguese 01-06-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 01-06-2023
Public Assessment Report Public Assessment Report Portuguese 09-03-2016
Patient Information leaflet Patient Information leaflet Romanian 01-06-2023
Public Assessment Report Public Assessment Report Romanian 09-03-2016
Patient Information leaflet Patient Information leaflet Slovak 01-06-2023
Public Assessment Report Public Assessment Report Slovak 09-03-2016
Patient Information leaflet Patient Information leaflet Finnish 01-06-2023
Public Assessment Report Public Assessment Report Finnish 09-03-2016
Patient Information leaflet Patient Information leaflet Swedish 01-06-2023
Public Assessment Report Public Assessment Report Swedish 09-03-2016
Patient Information leaflet Patient Information leaflet Norwegian 01-06-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 01-06-2023
Patient Information leaflet Patient Information leaflet Icelandic 01-06-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 01-06-2023
Patient Information leaflet Patient Information leaflet Croatian 01-06-2023
Public Assessment Report Public Assessment Report Croatian 09-03-2016

Search alerts related to this product

View documents history